Perspective Therapeutics reports updated Phase 1/2a data for [212Pb]VMT-α-NET: 3 objective responses, no DLTs

Perspective Therapeutics, Inc.

Three objective responses (1 confirmed, 2 unconfirmed) in Cohort 2 at 5.0 mCi dose; 5 stable disease; 1 progressive disease.
No dose-limiting toxicities, grade 4/5 events, or SAEs reported; hematologic AEs were grade 1-2 only.
Additional 11 patients dosed in Cohort 2 since August 2024, totaling 18 as of Dec 31, 2024.
Company pursuing dose escalation to Cohort 3 after FDA consultation; data submitted to FDA in December 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.